IL266518A - Methods for the treatment of pulmonary hypertension with combinations of Relinfag and other substances - Google Patents

Methods for the treatment of pulmonary hypertension with combinations of Relinfag and other substances

Info

Publication number
IL266518A
IL266518A IL266518A IL26651819A IL266518A IL 266518 A IL266518 A IL 266518A IL 266518 A IL266518 A IL 266518A IL 26651819 A IL26651819 A IL 26651819A IL 266518 A IL266518 A IL 266518A
Authority
IL
Israel
Prior art keywords
ralinepag
agents
combinations
methods
treating pah
Prior art date
Application number
IL266518A
Other languages
English (en)
Hebrew (he)
Original Assignee
Arena Pharm Inc
Clapp Lucie H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc, Clapp Lucie H filed Critical Arena Pharm Inc
Publication of IL266518A publication Critical patent/IL266518A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL266518A 2016-11-10 2019-05-08 Methods for the treatment of pulmonary hypertension with combinations of Relinfag and other substances IL266518A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662420515P 2016-11-10 2016-11-10
US201762530533P 2017-07-10 2017-07-10
PCT/US2017/061116 WO2018089804A1 (en) 2016-11-10 2017-11-10 Methods of treating pah with combinations of ralinepag and other agents

Publications (1)

Publication Number Publication Date
IL266518A true IL266518A (en) 2019-07-31

Family

ID=60451197

Family Applications (2)

Application Number Title Priority Date Filing Date
IL266518A IL266518A (en) 2016-11-10 2019-05-08 Methods for the treatment of pulmonary hypertension with combinations of Relinfag and other substances
IL323354A IL323354A (en) 2016-11-10 2025-09-14 Methods for treating pulmonary hypertension with combinations of relinfag and other substances

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL323354A IL323354A (en) 2016-11-10 2025-09-14 Methods for treating pulmonary hypertension with combinations of relinfag and other substances

Country Status (10)

Country Link
US (1) US12377067B2 (enExample)
EP (1) EP3538154B1 (enExample)
JP (3) JP2019533713A (enExample)
KR (3) KR20200015439A (enExample)
CN (2) CN119367341A (enExample)
AU (2) AU2017357759A1 (enExample)
CA (1) CA3043283A1 (enExample)
IL (2) IL266518A (enExample)
MA (1) MA46750A (enExample)
WO (1) WO2018089804A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017357759A1 (en) 2016-11-10 2019-06-06 Arena Pharmaceuticals, Inc. Methods of treating PAH with combinations of ralinepag and other agents
KR102432505B1 (ko) 2017-03-01 2022-08-12 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
WO2019222764A1 (en) * 2018-05-16 2019-11-21 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
CN108721296B (zh) * 2018-07-03 2019-04-05 中国人民解放军总医院 一种化合物在治疗或预防高原病中的用途
CN112638865B (zh) * 2018-09-06 2022-07-26 广东东阳光药业有限公司 药物共晶体及其制备方法
MX2021007455A (es) 2018-12-21 2021-08-05 Actelion Pharmaceuticals Ltd Composicion farmaceutica para el tratamiento de hipertension arterial pulmonar.
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof
US20250282716A1 (en) 2024-03-11 2025-09-11 United Therapeutics Corporation Methods of making ip-receptor agonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085844A1 (en) 1991-12-27 1993-06-28 Nobuyuki Hamanaka Fused benzeneoxyacetic acid derivatives
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
US20040048844A1 (en) 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
WO2002055484A1 (en) 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
US20030144350A1 (en) 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
EP1431267A4 (en) 2001-08-09 2004-12-22 Ono Pharmaceutical Co COMPOUNDS DERIVED FROM CARBOXYLIC ACID AND MEDICAMENTS COMPRISING SUCH COMPOUNDS AS ACTIVE INGREDIENT
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TWI293715B (en) 2002-10-10 2008-02-21 Sipix Imaging Inc A method for inducing or enhancing the threshold of an electrophoretic display, an electrophoretic fluid and an electrophoretic display
CN101723891A (zh) 2003-02-10 2010-06-09 沃泰克斯药物股份有限公司 通过使n-芳基氨基甲酸酯与卤代杂芳基反应制备n-杂芳基-n-芳基胺的方法和类似方法
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
JP2008510726A (ja) 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
WO2007051255A1 (en) 2005-11-04 2007-05-10 The University Of Sydney Process for the preparation of compounds containing an azacyclic ring system
US20080075692A1 (en) 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
KR20220031743A (ko) 2008-03-18 2022-03-11 아레나 파마슈티칼스, 인크. 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제
BRPI0921369B8 (pt) 2008-11-26 2021-05-25 Arena Pharm Inc composto modulador do receptor de prostaciclina (pgi2), sua composição, sua composição farmacêutica, seus usos, bem como processos para a preparação das referidas composições
ES2548882T3 (es) 2008-12-08 2015-10-21 Arena Pharmaceuticals, Inc. Moduladores del receptor de prostaciclina (PGl2) útiles para el tratamiento de trastornos relacionados con los mismos
EP2480526A1 (en) * 2009-09-23 2012-08-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of pgi2 receptor agonists
US9388154B2 (en) * 2011-09-12 2016-07-12 Lund Biotechnology PBC Process for preparing synthetic prostacyclins
JP6357481B2 (ja) * 2012-11-30 2018-07-11 インスメッド， インコーポレイテッド プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法
NZ731751A (en) 2014-10-23 2023-07-28 Arena Pharm Inc Method of treating conditions related to the pgi2 receptor
WO2016114993A1 (en) * 2015-01-13 2016-07-21 Selten Pharma, Inc. Combination therapy for pulmonary hypertension
AU2017357759A1 (en) 2016-11-10 2019-06-06 Arena Pharmaceuticals, Inc. Methods of treating PAH with combinations of ralinepag and other agents

Also Published As

Publication number Publication date
KR20200015439A (ko) 2020-02-12
WO2018089804A1 (en) 2018-05-17
CN110691612A (zh) 2020-01-14
CA3043283A1 (en) 2018-05-17
AU2017357759A1 (en) 2019-06-06
CN110691612B (zh) 2024-11-08
US20190321328A1 (en) 2019-10-24
WO2018089804A9 (en) 2018-06-21
US12377067B2 (en) 2025-08-05
EP3538154B1 (en) 2025-09-03
EP3538154A1 (en) 2019-09-18
IL323354A (en) 2025-11-01
JP2025131627A (ja) 2025-09-09
CN119367341A (zh) 2025-01-28
JP2023029865A (ja) 2023-03-07
KR20230021186A (ko) 2023-02-13
KR20240068077A (ko) 2024-05-17
AU2023263497B2 (en) 2025-09-18
JP2019533713A (ja) 2019-11-21
AU2023263497A1 (en) 2023-11-30
MA46750A (fr) 2019-09-18

Similar Documents

Publication Publication Date Title
IL323656A (en) Neoantigens and methods for using them
IL323354A (en) Methods for treating pulmonary hypertension with combinations of relinfag and other substances
IL259570A (en) Combined therapy and their uses and methods
IL255463A (en) Methods and kits for treating depression
IL274865A (en) Treatment methods with asparaginase
PL3548033T3 (pl) Związki i sposoby ich stosowania
GB2539350B (en) Amyloid targeting agents and methods of using the same
IL282482A (en) Variants of protoxin-II and methods of use
PT3448516T (pt) Aparelhos de fototerapia
EP3133919A4 (en) Agents and methods for treatment of pathogens
GB201609786D0 (en) Compounds and method of use
IL251885A0 (en) Noscapinoid-Producing Bacteria and Methods for Their Preparation and Use
IL282508A (en) Variants of protoxin-II and methods of use
IL254825A0 (en) Methods of treatment with Tesalisib
EP3134108A4 (en) Agents and methods of treatment
GB201511799D0 (en) Composition and methods of treatment
IL265387A (en) Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
GB201817198D0 (en) Treatment ported sub and method of use
IL255012A0 (en) Preparations and methods for treating skin conditions
GB201605127D0 (en) Composition and methods of treatment
GB2541786B (en) Jig and method of use thereof
HK40013586A (zh) 采用ralinepag与其他药剂的组合治疗pah的方法
GB201503371D0 (en) Methods of screening and treatment
SG11201804140PA (en) Acidic-gas treating agent and acidic-gas treating method
AU2014901480A0 (en) Agents and methods of treatment